FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a medicinal agent for treating a malignant neoplasm comprising a combination of a CCR8 antibody and an anti-PD-1 antibody or an anti-PD-L1 antibody, wherein the anti-CCR8 antibody is an antibody with ADCC activity and is a CCR8-neutralizing antibody. Group of inventions also relates to the use of a medicinal agent containing an anti-CCR8 antibody in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating a malignant neoplasm; pharmaceutical composition for treating a malignant neoplasm containing an anti-CCR8 antibody.
EFFECT: group of inventions provides tumour regression.
26 cl, 28 ex, 3 tbl, 38 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
